share_log

Positive Earnings Growth Hasn't Been Enough to Get Baolingbao BiologyLtd (SZSE:002286) Shareholders a Favorable Return Over the Last Three Years

Positive Earnings Growth Hasn't Been Enough to Get Baolingbao BiologyLtd (SZSE:002286) Shareholders a Favorable Return Over the Last Three Years

在過去的三年中,儘管寶龍寶生物(SZSE:002286)的盈利增長表現良好,但股東們並未獲得良好的回報。
Simply Wall St ·  07/02 19:12

This week we saw the Baolingbao Biology Co.,Ltd. (SZSE:002286) share price climb by 19%. But that cannot eclipse the less-than-impressive returns over the last three years. Truth be told the share price declined 36% in three years and that return, Dear Reader, falls short of what you could have got from passive investing with an index fund.

上週,保齡寶股份有限公司(SZSE:002286)的股票價格上漲了19%,但不能掩蓋過去三年收益不佳的事實。 事實上,股價在三年內下跌了36%,親愛的讀者,這一回報不如您可以從指數基金的被動投資中獲得的回報。

While the last three years has been tough for Baolingbao BiologyLtd shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.

雖然過去三年對保齡寶股份有限公司的股東來說非常艱難,但上週顯示了一些希望的跡象。 因此,讓我們查看更長期的基本面,看看它們是否是負回報的推動因素。

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

引用巴菲特的話,“船隻會在世界各地航行,但扁平地球協會將空前盛行。市場上的價格和價值將繼續存在巨大差異… ”檢查市場情緒如何隨時間變化的一種方法是查看公司的股價與每股收益(EPS)之間的互動。

During the unfortunate three years of share price decline, Baolingbao BiologyLtd actually saw its earnings per share (EPS) improve by 11% per year. This is quite a puzzle, and suggests there might be something temporarily buoying the share price. Or else the company was over-hyped in the past, and so its growth has disappointed.

在不幸的三年股價下跌期間,保齡寶股份有限公司的每股收益(EPS)實際上每年提高了11%。 這是一個相當棘手的問題,並表明股價可能有一些暫時的支撐。 或者公司過去被過度炒作,因此其增長令人失望。

Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics.

由於EPS的變化似乎與股價的變化不相關,因此值得查看其他指標。

The modest 1.3% dividend yield is unlikely to be guiding the market view of the stock. The company has kept revenue pretty healthy over the last three years, so we doubt that explains the falling share price. There doesn't seem to be any clear correlation between the fundamental business metrics and the share price. That could mean that the stock was previously overrated, or it could spell opportunity now.

1.3%的小額股息收益率不可能指導股市對該股票的看法。過去三年,公司的營業收入保持得相當穩健,因此我們懷疑這解釋了股價下跌的原因。 基本業務指標與股價之間似乎沒有明顯的相關性。 這可能意味着該股票先前被高估了,或者現在可能有機會。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下面的圖表顯示了收益和營收隨時間的變化情況(通過單擊圖像揭示確切的值)。

earnings-and-revenue-growth
SZSE:002286 Earnings and Revenue Growth July 2nd 2024
SZSE:002286股票的收益和營收增長2024年7月2日

Take a more thorough look at Baolingbao BiologyLtd's financial health with this free report on its balance sheet.

使用有關其資產負債表的免費報告更全面地了解保齡寶股份有限公司的財務狀況。

A Different Perspective

不同的觀點

While the broader market lost about 16% in the twelve months, Baolingbao BiologyLtd shareholders did even worse, losing 30% (even including dividends). However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Longer term investors wouldn't be so upset, since they would have made 2%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Baolingbao BiologyLtd better, we need to consider many other factors. Even so, be aware that Baolingbao BiologyLtd is showing 3 warning signs in our investment analysis , you should know about...

雖然總體市場在十二個月中損失了約16%,但保齡寶股份有限公司的股東表現得更糟糕,包括股息在內,損失了30%。 然而,股價可能僅僅受到整體市場恐慌的影響。 如果基本數據繼續表明長期可持續增長,目前的拋售可能是值得考慮的機會。 長期的投資者不會那麼不安,因爲他們每年可以獲得2%的回報,在五年內實現。 要更好地了解保齡寶股份有限公司,跟蹤股價長期表現總是很有趣的。 但是,需要考慮許多其他因素才能更好地理解。 無論如何,請注意,保齡寶股份有限公司的投資分析顯示出3個警告信號,您應該知道......

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果您願意查看另一家公司-具有潛在更優質財務狀況的公司-則不要錯過這個免費的公司列表,這些公司已經證明他們可以增長收益。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論